These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 25356988)

  • 1. Autophagy controls BCG-induced trained immunity and the response to intravesical BCG therapy for bladder cancer.
    Buffen K; Oosting M; Quintin J; Ng A; Kleinnijenhuis J; Kumar V; van de Vosse E; Wijmenga C; van Crevel R; Oosterwijk E; Grotenhuis AJ; Vermeulen SH; Kiemeney LA; van de Veerdonk FL; Chamilos G; Xavier RJ; van der Meer JW; Netea MG; Joosten LA
    PLoS Pathog; 2014 Oct; 10(10):e1004485. PubMed ID: 25356988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphism in autophagy gene ATG2B is not associated with bladder cancer recurrence after intravesical Bacillus Calmette-Guerin (BCG) immunotherapy in Asian patients.
    Zang Z; Lim YK; Chan YH; Raman L; Esuvaranathan K; Chiong E; Mahendran R
    Urol Oncol; 2021 Apr; 39(4):238.e1-238.e7. PubMed ID: 33250346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacillus Calmette-Guerin (BCG): Its fight against pathogens and cancer.
    Sfakianos JP; Salome B; Daza J; Farkas A; Bhardwaj N; Horowitz A
    Urol Oncol; 2021 Feb; 39(2):121-129. PubMed ID: 33262028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prophylactic effect of inductive intravesical instillation of Bacillus Calmette-Guerin on postoperative recurrence of bladder cancer].
    Yi SH; Ye G; Wang XW; Jin HS; Zhang YN; Yan ZL
    Ai Zheng; 2008 Nov; 27(11):1208-11. PubMed ID: 19000455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is intravesical Bacillus Calmette-Guérin therapy superior to chemotherapy for intermediate-risk non-muscle-invasive bladder cancer? An ongoing debate.
    Han KS; You D; Jeong IG; Kwon T; Hong B; Hong JH; Ahn H; Ahn TY; Kim CS
    J Korean Med Sci; 2015 Mar; 30(3):252-8. PubMed ID: 25729246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bacillus Calmette-Guérin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections.
    Larsen ES; Joensen UN; Poulsen AM; Goletti D; Johansen IS
    APMIS; 2020 Feb; 128(2):92-103. PubMed ID: 31755155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bacillus Calmette-Guerin mechanism of action: the role of immunity, apoptosis, necrosis and autophagy.
    DiPaola RS; Lattime EC
    J Urol; 2007 Nov; 178(5):1840-1. PubMed ID: 17868741
    [No Abstract]   [Full Text] [Related]  

  • 8. Intravesical bacille Calmette-Guérin (BCG) in immunologically compromised patients with bladder cancer.
    Herr HW; Dalbagni G
    BJU Int; 2013 May; 111(6):984-7. PubMed ID: 23351086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
    Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
    Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trained immunity as a molecular mechanism for BCG immunotherapy in bladder cancer.
    van Puffelen JH; Keating ST; Oosterwijk E; van der Heijden AG; Netea MG; Joosten LAB; Vermeulen SH
    Nat Rev Urol; 2020 Sep; 17(9):513-525. PubMed ID: 32678343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
    Shintani Y; Sawada Y; Inagaki T; Kohjimoto Y; Uekado Y; Shinka T
    Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin.
    Kamat AM; Briggman J; Urbauer DL; Svatek R; Nogueras González GM; Anderson R; Grossman HB; Prat F; Dinney CP
    Eur Urol; 2016 Feb; 69(2):197-200. PubMed ID: 26119560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The fate of bacillus Calmette-Guerin after intravesical instillation.
    Durek C; Richter E; Basteck A; Rüsch-Gerdes S; Gerdes J; Jocham D; Böhle A
    J Urol; 2001 May; 165(5):1765-8. PubMed ID: 11342972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BCG Vaccination Protects against Experimental Viral Infection in Humans through the Induction of Cytokines Associated with Trained Immunity.
    Arts RJW; Moorlag SJCFM; Novakovic B; Li Y; Wang SY; Oosting M; Kumar V; Xavier RJ; Wijmenga C; Joosten LAB; Reusken CBEM; Benn CS; Aaby P; Koopmans MP; Stunnenberg HG; van Crevel R; Netea MG
    Cell Host Microbe; 2018 Jan; 23(1):89-100.e5. PubMed ID: 29324233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravesical bacillus Calmette-Guerin (BCG) instillation for primary and recurring T1G3 bladder cancers.
    Okamura T; Akita H; Ando R; Kawai Y; Tozawa K; Kohri K
    Asian Pac J Cancer Prev; 2010; 11(4):1107-10. PubMed ID: 21133632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of bacillus Calmette-Guerin refractory non-muscle invasive bladder cancer.
    Turker P; Turkeri L
    Arch Esp Urol; 2013 Nov; 66(9):833-40. PubMed ID: 24231293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guérin in patients with high-risk non-muscle-invasive bladder cancer.
    Fujita N; Hatakeyama S; Momota M; Kido K; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
    Urol Oncol; 2020 Aug; 38(8):684.e17-684.e24. PubMed ID: 32278732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determining optimal maintenance schedules for adjuvant intravesical bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer: a systematic review and network meta-analysis.
    Huang Z; Liu H; Wang Y; Zhang C; Xu T
    Curr Med Res Opin; 2017 Aug; 33(8):1379-1387. PubMed ID: 28471272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should intravesical Bacillus Calmette-Guérin be employed in transplant recipients with bladder carcinoma?
    Sun HY; Singh N
    Transpl Infect Dis; 2010 Aug; 12(4):358-62. PubMed ID: 20412534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can we treat bladder cancer with intravesical Bacillus Calmette-Guerin in patients with prior tuberculosis infection? A population-based cohort study.
    Hsu CW; Chiu YC; Hu HY; Fan YH; Hong SC; Cheng WM
    BMC Urol; 2020 Jul; 20(1):91. PubMed ID: 32641099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.